14th February 2019

In this workshop, we will explore how a good early stage valuation is actually a mix of building right narratives backed by numbers. We will also bust a few myths such as “early stage products cannot be valued” or “your product is so unique that it is difficult to find comparable companies”.

Most of the time, valuation is considered a numbers’ game or building complex models or being too subjective. Does creating complex models lead to a good valuation? If it’s too subjective, how do some of the funds focused on Value investing make money? Farmantra is ready with all the answers and delighted to meet young Biotechs.